Telemedicine follow-up for early laryngeal cancer patients
Telemedicine Follow-up for Pre-malignant and Malignant Glottic Lesions: a Randomised Controlled Trial Study Protocol Comparing Care Close to Home Versus Standard of Care
This study tests if follow-up care through Telemedicine is just as good as in-person visits for people with early laryngeal cancer, especially for those who live far from treatment centers.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 140 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Medical Center Groningen Academic / other |
| Locations | 1 site (Groningen, Provincie Groningen) |
| Trial ID | NCT06940505 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of Telemedicine follow-up as an alternative to traditional in-person follow-up care for patients treated for early glottic cancer. It compares patient satisfaction and safety outcomes, such as recurrence rates and complications, between those receiving Telemedicine follow-up and those receiving standard care at a specialized head and neck oncology center. Participants are randomly assigned based on their travel distance to the center, with the aim of determining if remote evaluations can maintain quality care for patients living far from specialized facilities.
Who should consider this trial
Good fit: Ideal candidates are patients who have undergone treatment for early stage glottic squamous cell carcinoma and live at least 45 minutes away from a specialized oncology center.
Not a fit: Patients who are still undergoing follow-up for other head and neck cancers at the oncology center may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a more accessible and satisfactory follow-up care option for patients with early laryngeal cancer.
How similar studies have performed: Other studies have shown promising results with telemedicine approaches in various medical fields, suggesting potential success for this novel application in laryngeal cancer follow-up.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients who underwent TOLS for early stage glottic squamous cell carcinoma (T1 or carcinoma-in-situ) * a one-way travel time to the HNOC of ≥45 minutes (intervention group) or \< 30 minutes (control group) * within 2 years postoperatively * can speak and write Dutch Exclusion Criteria: * Patients will be excluded if they continue to undergo follow-up for other (head and neck) cancers in the HNOC.
Where this trial is running
Groningen, Provincie Groningen
- University Medical Center Groningen — Groningen, Provincie Groningen, Netherlands (Recruiting)
Study contacts
- Principal investigator: Boudewijn E.C. Plaat, MD, PhD — UMC Groningen
- Study coordinator: Nathalie F van Rhee, MD
- Email: n.f.van.rhee@umcg.nl
- Phone: +31614915058
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.